Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 9,544 matching trials from the live ClinicalTrials.gov search.

Filters: Birmingham, Alabama Clear all

Conditions: Acute Myocardial Infarction
Interventions: CSL112, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 1,267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more

Conditions: Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Surgical Procedure, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Docetaxel, Vinorelbine, Nivolumab, Pembrolizumab, Atezolizumab, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 415
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 319 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Atrial Fibrillation
Interventions: Dronedarone, Placebo (for Dronedarone); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 92
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 79 more

Conditions: Physical Activity
Interventions: HIPP, Wellness contact control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years to 69 Years · Female only
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Atrial Fibrillation New Onset
Interventions: CorMatrix ECM for Pericardial Closure; Device
Lead sponsor: Elutia Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 16
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 12 more

Conditions: Epilepsy, Partial
Interventions: Levetiracetam, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 1 Month to 4 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more

Conditions: Fecal Incontinence, Bowel Incontinence
Interventions: ES-130; Device
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Birmingham, Alabama • Downey, California • La Jolla, California + 6 more

Conditions: Antiretroviral Toxicity
Interventions: Not listed
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: Not listed
Enrollment: 5,169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2025
U.S. locations: 20
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer
Interventions: proteomic profiling, surface-enhanced laser desorption/ionization-time of flight mass spectrometry, biopsy; Genetic · Other · Procedure
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 107
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Burbank, California + 80 more

Conditions: Orthodontic Treatment, Tooth Crowding, Orthodontics
Interventions: Aerodentis system, Invisalign clear aligner system; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 12 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: SARS-CoV 2
Interventions: SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1,225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 29
States / cities: Birmingham, Alabama • Chinle, Arizona • Phoenix, Arizona + 24 more

Conditions: Infections, Cytomegalovirus
Interventions: Blood collection, Urine collection, Saliva collection; Procedure
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 369 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Birmingham, Alabama • Stevensville, Michigan

Conditions: Symptomatic Genetic Dilated Cardiomyopathy
Interventions: danicamtiv, Placebo; Drug
Lead sponsor: Kardigan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Hantavirus Pulmonary Syndrome
Interventions: Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Osteoarthritis, OA Knee Pain, Arthritis
Interventions: RN624 (PF-04383119); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 24 more

Conditions: HIV Infections
Interventions: Abacavir sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 9 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more

Conditions: Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions: Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube; Drug · Device
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 30 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 16
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more

Conditions: HIV Infections, Kidney Diseases
Interventions: Maraviroc, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more

Conditions: Food Allergy
Interventions: Ligelizumab 120 mg, Ligelizumab 240 mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 57 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 21 more

Conditions: Draining Hematoma
Interventions: Standard Pressure Dressing, VAC; Procedure · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
Interventions: CLN-049; Drug
Lead sponsor: Cullinan Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 13 more

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Decision Making, Shared, Family Caregiving, Chronic Kidney Disease
Interventions: ImPart - Improving Chronic Kidney Disease Decisional Partnerships; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected Patients

Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers

Home-based, Individually-tailored Physical Activity Print Intervention for African American Women in the Deep South

Evaluation Of New Onset Postoperative Atrial Fibrillation

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

Neuromodulation for Accidental Bowel Leakage

Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

Assessment of the Efficacy of the Aerodentis System

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

A Study in Adolescent Females to Explore Cytomegalovirus Infection

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

Open-label Extension Study Of RN624

Blood Levels of Abacavir After One Dose in HIV-Infected Children and Adolescents

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

Long-term Extension Study of Ligelizumab in Food Allergy

Vacuum Assisted Closure as a Treatment for Draining Hematomas

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)